O

OrganOx

Portable, automated organ perfusion for transplantation

Regulatory Affairs Specialist

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Madison, NJ, USA
HybridHybrid in Madison, NJ, approximately 2 days per week in office; up to 5% additional travel.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Working knowledge of medical device regulatory requirements and FDA regulatory processes.
  • Ability to prepare clear and well-organized regulatory documentation and submissions.
  • Working knowledge of medical device regulatory requirements in one or more international markets such as the European Union, Canada, and Australia.
  • Experience with regulatory information management systems or similar data systems.
  • Experience collaborating cross-functionally with Manufacturing, Quality, Research and Development, Clinical, Marketing, and other business functions.
  • Strong organizational skills and attention to detail, with an ability to manage multiple priorities.
  • Excellent verbal communication and technical writing skills.
  • Minimum of a bachelor's degree in a technical discipline (Engineering or Life Sciences), or another related area of study.
  • Minimum of 3 years of regulatory affairs experience within the medical device or similar industry.
  • Ability to travel 5% domestically and/or internationally.
Responsibilities
  • Support the preparation, compilation, review, and submission of regulatory filings for OrganOx products in the United States, European Union, Canada, Australia, and other markets.
  • Work collaboratively across the Regulatory Affairs function, including software, retained unit, disposable set, labelling, and regulatory systems, to coordinate regulatory deliverables and maintain alignment across product areas.
  • Support regulatory authority and Notified Body interactions associated with assigned submissions and regulatory activities.
  • Create, maintain, and periodically reconcile regulatory records to ensure accurate representation of product registrations, submissions, approvals, certificates, licenses, regulatory commitments, market status, and other regulatory information.
  • Support configuration, process improvements, reporting, and implementation of new functionality within Rimsys.
  • Maintain alignment between regulatory records, change-control activities, approved product configurations, and other applicable business systems.
  • Support maintenance of regulatory registrations, renewals, annual reports, and other recurring regulatory obligations.
  • Collaborate with Regulatory Affairs and cross-functional stakeholders to support assigned regulatory activities and ensure regulatory requirements and deliverables are appropriately communicated and completed.
  • Adhere to the letter and spirit of OrganOx’s Code of Conduct and all other company policies.
Desired Qualifications
  • Experience with Rimsys.

About the company

OrganOx develops and commercializes organ perfusion technology to keep donor organs viable for transplantation. The flagship metra device perfuses livers with oxygenated blood at body temperature, delivering nutrients and drugs to mimic normal physiology and allow viability assessment for up to 24 hours. Unlike traditional cold storage, it maintains normothermic conditions and offers direct organ assessment and longer preservation; it leases devices to transplant centers and uses disposable sets. Its goal is to increase transplantable livers and expand to other organs and applications.

Company Size

201-500

Company Stage

Acquired

Total Funding

$73.9M

Headquarters

Oxford, United Kingdom

Founded

2008

Get referred to OrganOx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Metra gained FDA approval for air transport on September 18, 2025, expanding logistics.
  • OrganOx said metra has been used in over 10,000 liver transplants by August 2026.
  • NICE endorsed routine NHS funding, which should accelerate U.K. adoption and reimbursement.

What critics are saying

  • TransMedics competes directly, and NICE excluded its OCS Liver from NHS funding.
  • OrganOx remains transplant-liver focused; failure to extend beyond metra concentrates revenue risk.
  • Post-acquisition integration into Terumo can slow execution and dilute OrganOx's entrepreneurial speed.

What makes OrganOx unique

  • OrganOx metra keeps donor livers metabolically active, enabling viability assessment before transplant.
  • Terumo completed the $1.5 billion acquisition on October 30, 2025, validating the platform.
  • NICE HTG780 named metra for routine NHS funding across England on August 20, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Wellness Program
  • Employee Discounts

Growth & Insights and Company News

6 month growth

1%

1 year growth

-1%

2 year growth

6%
TXF
Aug 24th, 2026
Terumo gets ECA support for OrganOx acquisition.

Terumo gets ECA support for OrganOx acquisition. Manufacturing & equipment Asia-Pacific, Europe JBIC signed a JPY49 billion ($307.1 million) loan with Terumo to fund part of its acquisition of UK organ preservation device company OrganOx. The financing is being provided in co-financing with private financial institutions, bringing the total co-financing amount to JPY99 billion ($620.4... Exclusive subscriber content... Not yet a subscriber? Join TXF Limited today to continue accessing content without any restrictions Or to request access to TXF Intelligence contact TXF Limited

Medical Device Network
Jan 7th, 2026
Terumo announces US launch of safety syringe

Terumo announces US launch of safety syringe. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. Terumo Medical has announced the launch of its SurTract Safety Syringe in the US, incorporating Roncadelle Operations' SafeR passive safety technology. The syringe will be distributed to clinics, emergency-care settings and hospitals across the country starting from the first quarter of this year. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. This feature withdraws the needle into the plunger after use immediately, aiming to reduce needle-stick injury risks for healthcare professionals. The system also maintains standard clinical technique while enhancing safety and ease of use. The SurTract Safety Syringe also offers a needle selection that can be customised specifically for use with SurTract Syringes, enabling physicians to choose combinations best suited to patient needs. In addition, the syringe provides a blunt needle option, which helps prevent dullness and allows for needle replacement during aspiration. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. The design contributes to less medical waste by eliminating an external plastic safety sheath. Terumo vice-president Bob Klock said: "The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections. It gives healthcare providers more - and better - treatment options for their patients, which is our ultimate goal." Roncadelle operations chief business development officer Dr Fred Metzmann said: "Terumo has significantly advanced injection safety with the integration of our SafeR technology. Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals." The company's SafeR product line includes needle-guard systems and passive safety syringes designed for safe injection and protection in clinical environments. In October 2025, Terumo completed its previously announced acquisition of OrganOx for nearly $1.5bn after meeting all necessary regulatory and closing requirements.

MD+DI
Aug 28th, 2025
Medtech in a Minute: A Verily Big Decision & More

Terumo has agreed to acquire OrganOx for about $1.5B. OrganOx specializes in advanced Normothermic Machine Perfusion devices for organ preservation.

UK Tech News
Aug 26th, 2025
Japan's Terumo acquires Oxford health tech in $1.5bn deal

OrganOx, a University of Oxford spinout that has developed an automated device to preserve organs in transit, has been acquired by Tokyo-based medical manufacturer Terumo for $1.5bn (£1.1bn).

TechStartups
Aug 25th, 2025
Oxford spinout OrganOx acquired by Terumo for $1.5 billion, largest university spinout exit in UK history

From lab to $1.5B exit: Oxford spinout OrganOx acquired by Terumo.